# EU-1-11-739_public-assessment-report_20111215_20111215_dasselta--epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES
HEALTH
22 September 2011
EMA/895265/2011
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Dasselta
International nonproprietary name: desloratadine
Procedure No. EMEA/H/C/002310
Assessment Report as adopted by the CHMP with
all information of a commercially confidential nature deleted.
7 Westferry Circus . Canary Wharf . London E14 4HB . United Kingdom
Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545
E-mail info@ema.europa.eu Website www.ema.europa.eu
An agency of the European Union
European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged.
Table of contents
1
Background information on the procedure
3
1.1 Submission of the dossier
3
1.2 Steps taken for the assessment of the product
4
2
Scientific discussion
4
2.1
Introduction
4
2.2
Quality aspects
5
2.3 Non- Clinical aspects
7
8
2.4 Clinical Aspects.
12
2.5 Pharmacovigilance
3
Benefit-Risk Balance
13
4 Recommendation
14
Dasselta Novo Mesto
Assessment report
EMA/895265/2011
Page 2/14
